EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Diversity of US participants in AstraZeneca-sponsored clinical trials

Claudia Cabrera, Daniel Fernández-Llaneza, Zara Ghazoui, Sofia D'Abrantes, M Alejandro Esparza-Franco, Charles Sopp, Beata Maj, Victoria L Chiou, Barbara Valastro, Menelas N Pangalos, Susan Galbraith, Serban Ghiorghiu und 1 weitere

Contemporary Clinical Trials · 2024

DOI: 10.1016/j.cct.2024.107496 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Contemporary Clinical Trials, 2024. Verfasst von Claudia Cabrera und 12 weiteren Autor:innen. Beteiligte Einrichtung: Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden. Electronic address: Claudia.S.Cabrera@astrazeneca.com. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca Mölndal, AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: To develop medicines that are safe and efficacious to all patients, clinical trials must enroll appropriate target populations, but imbalances related to race, ethnicity and sex have been reported. A comprehensive analysis and improvement in understanding representativeness of patient enrollment in industry-sponsored trials are key public health needs. METHODS: We assessed race/ethnicity and sex representation in AstraZeneca (AZ)-sponsored clinical trials in the United States (US) from 2010 to 2022, compared with the 2019 US Census. RESULTS: In total, 246 trials representing 95,372 patients with complete race/ethnicity and sex records were analyzed. The proportions of different race/ethnicity subgroups in AZ-sponsored clinical trials and the US Census were similar (White: 69.5% vs 60.1%, Black or African American: 13.3% vs 12.5%, Asian: 1.8% vs 5.8%, Hispanic: 14.4% vs 18.5%). We also observed parity in the proportions of males and females between AZ clinical trials and US Census (males: 52.4% vs 49.2%, females: 47.6% vs 50.8%). Comparisons of four distinct therapy areas within AZ (Respiratory and Immunology [R&I]; Cardiovascular, Renal, and Metabolism [CVRM]; Solid Tumors; and Hematological Malignancies), including by trial phases, revealed greater variability, with proportions observed above and below US Census levels. CONCLUSION: This analysis provides the first detailed insights into the representativeness of AZ trials. Overall, the proportions of different race/ethnicity and sex subgroups in AZ-sponsored clinical trials were broadly aligned with the US Census. We outline some of AZ's planned health equity initiatives that are intended to continue to improve equitable patient enrollment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicFemaleHumansMaleDrug IndustryEthnicityPatient SelectionRacial GroupsSex FactorsUnited StatesWhiteBlack or African AmericanAsianHispanic or Latino

Stichwörter der Autor:innen

AstraZenecaClinical trialDiversityEquityEthnicityRace

Autor:innen und Institutionen

  • Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden. Electronic address: Claudia.S.Cabrera@astrazeneca.com.
  • Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Data Science and Artificial Intelligence, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK.
  • Chief Medical Office, AstraZeneca, Gothenburg, Sweden.
  • Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Research and Development Patient Science, Chief Medical Office, AstraZeneca, Gothenburg, Sweden.

Förderung

  • AstraZeneca Mölndal
  • AstraZeneca PLC

Zitieren

APA

Cabrera, C., Fernández-Llaneza, D., Ghazoui, Z., D'Abrantes, S., Esparza-Franco, M. A., Sopp, C., Maj, B., Chiou, V. L., Valastro, B., Pangalos, M. N., Galbraith, S., Ghiorghiu, S., & Massacesi, C. (2024). Diversity of US participants in AstraZeneca-sponsored clinical trials. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2024.107496

Vancouver

Cabrera C, Fernández-Llaneza D, Ghazoui Z, D'Abrantes S, Esparza-Franco MA, Sopp C, et al. Diversity of US participants in AstraZeneca-sponsored clinical trials. Contemporary Clinical Trials. 2024. doi:10.1016/j.cct.2024.107496

BibTeX
@article{Cabrera2024,
  author = {Cabrera, Claudia and Fernández-Llaneza, Daniel and Ghazoui, Zara and D'Abrantes, Sofia and Esparza-Franco, M Alejandro and Sopp, Charles and Maj, Beata and Chiou, Victoria L and Valastro, Barbara and Pangalos, Menelas N and Galbraith, Susan and Ghiorghiu, Serban and Massacesi, Cristian},
  title = {Diversity of US participants in AstraZeneca-sponsored clinical trials},
  journal = {Contemporary Clinical Trials},
  year = {2024},
  doi = {10.1016/j.cct.2024.107496}
}
Kostenlos starten →